In two analyses of spontaneous reports from the US Food and Drug Administration’s adverse event reporting system database, the reporting rates of thyroid cancer were 4.7 and 8 times higher, respectively, for GLP1 receptor agonists compared with other diabetes drugs.2, 3 In a meta-analysis based on 15 clinical trials that included at least one thyroid cancer outcome event, the odds ratio for thyroid cancer associated with GLP1 receptor agonists was 1.49 (95% confidence interval 0.83 to 2.66). The gene discussed is GLP1R; the disease is diabetes mellitus.